Safety of biologics in severe asthmatic patients with SARS-CoV-2 infection: A prospective study.

Sara Manti Alessandro GiallongoGiulia PecoraGiuseppe Fabio ParisiMaria PapaleEnza MulèDonatella AloisioNovella RotoloSalvatore Leonardi

Published in: Pediatric pulmonology (2023)

we showed that the scheduled dose of the biologic therapy can be administered safely on time in patients with SARS-CoV-2 infection, as the treatment did not result in adverse events or outcomes. This article is protected by copyright. All rights reserved.

Keyphrases

respiratory syndrome coronavirus
rheumatoid arthritis
early onset
sars cov
stem cells
lung function
type diabetes
metabolic syndrome
mesenchymal stem cells
air pollution
cell therapy
smoking cessation